Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial. J of Skin [Internet]. 2024 Nov. 18 [cited 2025 Apr. 4];8(6):s489. Available from: https://skin.dermsquared.com/skin/article/view/3134